Top

Published in:

01-06-2011 | Research Article

RETRACTED ARTICLE: Erucylphosphocholine induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells

Authors: Noriyuki Takai, Tami Ueda, Terukazu Ishii, Naoko Kira, Masakazu Nishida, Kaei Nasu, Hisashi Narahara

Published in: Tumor Biology | Issue 3/2011

Abstract

A membrane-targeted, lipophilic ether lipid of synthetic phospholipid analog, erucylphosphocholine (ErPC), induces apoptosis in some lines of human tumor cells. We investigated the effect of ErPC in the choriocarcinoma cell line, BeWo. BeWo cells were treated with various concentrations of ErPC, and changes in cell growth, the cell cycle, apoptosis, and related parameters were examined. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that BeWo cells were sensitive to the growth inhibitory effect of ErPC. Cell cycle analysis indicated that exposure to ErPC decreased the proportion of cells in the S phase and increased the proportion in the G0/G1 phases of the cell cycle. Induction of apoptosis was confirmed by Annexin V staining of externalized phosphatidylserine and by the loss of mitochondrial transmembrane potential. This induction occurred in conjunction with the altered expression of genes related to cell growth, malignant phenotype, and apoptosis. These results suggest that ErPC may serve as a therapeutic agent for the treatment of choriocarcinoma.

Jones WB, Cardinale C, Lewis Jr JL. Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experience. Int J Gynecol Cancer. 1997;7:27–33.CrossRefPubMed

Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol. 1984;19:173–81.CrossRefPubMed

Surwit EA, Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980;55:565–70.PubMed

Noseda A, Berens ME, White JG, Modest EJ. In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells. Cancer Res. 1988;48:1788–91.PubMed

Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitizers. Curr Med Chem Anticancer Agents. 2003;3:343–53.CrossRefPubMed

Jendrossek V, Müller I, Eibl H, Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene. 2003;22:2621–31.CrossRefPubMed

Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141–9.CrossRefPubMed

Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637–43.PubMed

Rimon G, Bazenet CE, Philpott KL, Rubin LL. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563–70.CrossRefPubMed

10.

Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001;61:6437–44.PubMed

11.

van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des. 2008;14:2061–74.CrossRefPubMed

12.

Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295–312.CrossRefPubMed

13.

Sherr CJ. G1 phase progression: cyclin on cue. Cell. 1994;79:551–5.CrossRefPubMed

14.

Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M. Erucylphosphocholine: pharmacokinetics, biodistribution, CNS accumulation and toxicity in the rat after intravenous application. Cancer Chemother Pharmacol. 1999;44:484–90.CrossRefPubMed

15.

Wang YZ, Chang YB, Xing C, Fu D. The interference effects of hexadecylphosphocholine on proliferation and membrane phospholipid metabolism in human myeloid leukemia cell lines. Int J Tissue React. 1998;20:101–7.PubMed

16.

Lucas L, Hernandez-Alcoceba R, Penalva V, Lacal JC. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene. 2001;20:1110–7.CrossRefPubMed

17.

Berkovic D, Bensch M, Bertram J, Wille T, Haase D, Binder C, et al. Effects of hexadecylphosphocholine on thrombocytopoiesis. Eur J Cancer. 2001;37:503–11.CrossRefPubMed

18.

Jendrossek V, Kugler W, Erdlenbruch B, Eibl H, Lang F, Lakomek M. Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations. Anticancer Res. 2001;21:3389–96.PubMed

19.

Berkovic D, Grunwald U, Menzel W, Unger C, Hiddemann W, Fleer EAM. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur J Cancer. 1995;31(A):2080–5.CrossRef

20.

Vink SR, van Blitterswijk WJ, Schellens JHM, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev. 2007;33:191–202.CrossRefPubMed

21.

Handrick R, Rudner J, Müller I, Eibl H, Belka C, Jendrossek V. Bcl-2 mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localization. Biochem Pharmacol. 2005;70:837–50.CrossRefPubMed

22.

van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther. 2007;6:2337–45.CrossRefPubMed

23.

Georgieva MC, Konstantinov SM, Topashka-Ancheva M, Berger MR. Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett. 2002;182:163–74.CrossRefPubMed

24.

Takai N, Ueda T, Nasu K, Narahara H. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;111:336–43.CrossRefPubMed

Title: RETRACTED ARTICLE: Erucylphosphocholine induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells
Authors: Noriyuki Takai
Tami Ueda
Terukazu Ishii
Naoko Kira
Masakazu Nishida
Kaei Nasu
Hisashi Narahara
Publication date: 01-06-2011
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-010-0152-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers

Detection of HPV by in situ hybridization in thin-layer (ThinPrep) cervicovaginal samples

Stable knockdown of S100A4 suppresses cell migration and metastasis of osteosarcoma

Identification of differential expressed transcripts in cervical cancer of Mexican patients

Immunohistochemical analysis of vascular density and area in colorectal carcinoma using different markers and comparison with clinicopathologic prognostic factors

The role of S100 genes in breast cancer progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer